Betablokátory u kardiovaskulárních onemocnění na počátku 21. století

Title in English Beta-blockers in cardiovascular diseases at the beginning of the 21st century


Year of publication 2017
Type Popularization text
MU Faculty or unit

Faculty of Medicine

Description Currently, beta blockers (BBs) represent a heterogenous group of drugs with different pharmacokinetic and pharmacodynamic properties and they should not be viewed as a uniform drug class. BBs have protective effects in almost all stages of cardiovascular damage. However, many analyses and pieces of information questioning this – unquestionable so far – role of BB have occurred lately. This review summarizes the new data concerning BBs use in the context hypertension, for secondary prevention of coronary artery disease and arrhythmias, and for treatment of chronic heart failure. BBs offer cardioprotection even to patients with COPD and peripheral artery disease (PAD). It is necessary to choose BBs with high cardiac selectivity and hydrophilic ones showing long enough effect and balanced renal and hepatic clearance.

You are running an old browser version. We recommend updating your browser to its latest version.

More info